Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ferrarotto, Renata
  • Metcalf, Robert
  • Rodriguez, Cristina P
  • Muzaffar, Jameel
  • Even, Caroline
  • Perez, Cesar Augusto
  • Van Herpen, Carla M L-
  • Oliva, Marc
  • Xia, Bing
  • Bowles, Daniel W
  • Popovtzer, Aharon
  • Winquist, Eric
  • Wirth, Lori J
  • Hao, Desiree
  • Kang, Hyunseok
  • Hotte, Sebastien
  • Stemmer, Salomon M
  • Mehra, Ranee
  • Worden, Francis P
  • Ho, Alan Loh

publication date

  • June 2022